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Short sentence summarising findings: In many low- and middle-income countries chest x-
rays are not free of charge for TB patients. 
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 2 
Even when tuberculosis (TB) care is free, impoverished patients, and their 3 
households, continue to incur unmanageable costs due to seeking and staying in 4 
care for the full duration of anti-tuberculosis treatment (1). By aggravating 5 
household vulnerability, these costs can prevent or delay diagnosis, treatment and 6 
successful outcome, leading to increased TB transmission, morbidity and mortality 7 
(2-4). The new World Health Organization (WHO)’s End TB Strategy places greater 8 
emphasis on ensuring universal free access to care, and it includes a target of 9 
elimination of associated catastrophic costs for TB patients and their households by 10 
2020 (5). 11 
 12 
Data from prevalence surveys has led to a renewed interest in CXRs as a triage test 13 
and a tool for active case finding (6, 7). Today CXRs are employed in many settings 14 
both for screening and as part of the diagnostic algorithm and follow-up.  If, 15 
however, CXRs are not provided free of charge to the patient, there is a risk that 16 
these may aggravate costs incurred by patients during their path to a TB diagnosis. 17 
 18 
We sought to provide a snapshot of current accessibility of CXRs to TB patients and 19 
patients accessing care with symptoms suggestive of TB (presumptive TB cases(8)) 20 
both geographically and financially. We consulted experts from 44 low and middle-21 
income countries; of these, 12 are from the 30 high TB burden and 10 from the 30 22 
high MDR-TB burden countries (Table 1), through an online survey with open and 23 
multiple-choice questions. The questionnaire was sent via email to staff working in 24 
National Tuberculosis Programmes (NTPs) or consultants and researchers working 25 
closely with NTPs. We received a response from 27 of them (61.4%).  26 
 27 
The survey asked about the availability and cost of CXR in public health facilities, role 28 
of CXR in the country’s diagnostic algorithm, provision of health insurance or other 29 
forms of social protection to TB patients and presumptive TB cases (Box 1). 30 
 31 
In most countries (19/27), CXRs are part of the routine diagnostic algorithm and 32 
follow-up. In over half of the countries (15/27, 55%) patients have to pay for a CXR 33 
 3 
examination in the public service. The cost for a CXR varies between USD 1.5 and 34 
USD 42 (median USD 7.8). The highest costs were reported from African countries 35 
(Figure 1). Costs were reported to vary even within countries:  prices ranged 36 
between USD 8.4 and 42 in Senegal, USD 5 and 20 in Zimbabwe dependent on the 37 
facility and the region. Some patients were exempt from payment: MDR-TB patients 38 
(Bolivia, Burkina Faso, Senegal), patients co-infected with HIV (Ghana, Burkina Faso), 39 
children under 5 (Bolivia, Burkina Faso, Viet Nam), patients categorised as very poor 40 
by their kebele (“neighbourhood”) leaders (Ethiopia) and patients under follow-up 41 
(Kyrgyzstan). In contrast sputum smear microscopy is provided free of charge in all 42 
countries. In countries where CXRs are also employed for monitoring progress during 43 
treatment, this exposes patients to even higher costs as they had to pay not only for 44 
diagnostic but also for follow-up CXR examinations.  45 
 46 
TB diagnostics and treatment is free of charge with the exception of CXRs in most 47 
low-income countries without a national health insurance scheme (such as 48 
Zimbabwe). The same holds true for middle-income countries (Viet Nam, Dominican 49 
Republic, Indonesia, Peru). However, those countries often have health insurance 50 
schemes covering the costs of CXRs. Health insurance schemes based on a 51 
contributory model (such as in Ghana) are only accessible to individuals employed in 52 
the formal sector. Hence the poorest, who are at greatest risk of TB, are left out of 53 
the health insurance scheme and are unable to access CXRs free of charge.  54 
 55 
Our analysis has limitations. It is likely that we underestimated the costs of CXRs for 56 
patients as we only considered direct medical costs, but hidden direct “out of 57 
pocket” costs such as transport costs (especially when CXR facilities are not on site) 58 
and food, as well as indirect costs due to loss of productivity, tend to account for a 59 
sizable proportion of expenditure on seeking and receiving care (1).  Patient costs 60 
surveys that are currently under way will provide useful insights and more 61 
comprehensive estimates. 62 
 63 
We focused on the public sector only. The private sector often represents the first 64 
point of care for most TB patients in many Asian countries (8). Data reported from 65 
 4 
Pakistan show that CXR costs in the private sector can be up to four times higher 66 
than in public health facilities (USD 2.5-8.0 vs. USD 1.5-2.0). 67 
 68 
Our survey is not representative of the global level, nor did it intend to. However, we 69 
covered 12 of the 30 high TB burden and 10 of the 30 high MDR-TB burden 70 
countries. Furthermore, we included countries from the three most affected 71 
continents (Figure 1). 72 
 73 
As prevalence surveys have shown, expanding the use of CXR has a great potential as 74 
a screening/triage tool and can contribute to achieving the ambitious targets set in 75 
the End TB Strategy (6).  However, the TB community needs to be aware that 76 
widespread use of CXRs might potentially aggravate costs for patients and 77 
presumptive TB cases. CXRs, similar to sputum smear microscopy and Xpert 78 
MTB/RIF, should be easily accessible and free of charge if employed for TB diagnosis 79 
and follow-up.  A recently published WHO policy document on chest radiography 80 
aptly states that CXRs should be free of charge and/or fully reimbursed by health 81 
insurance (9). Practical approaches to mitigate patient costs should also be provided 82 
to NTPs.  Harmonisation within and across countries and donors will be necessary. 83 
Another potential avenue to reducing the costs for patients is the extension of social 84 
protection interventions (such as cash transfers and health insurance) to cover all 85 
costs associated with TB diagnosis and treatment. This will require strong political 86 
commitment and dedicated resource, and it will be difficult to implement in the near 87 
future. 88 
 89 
In conclusion, the direct costs of CXR for patients are high. In many of the countries 90 
participating in this survey a large proportion of their population lives on less than 91 
USD 1.9 per day (10). Efforts are made to reduce financial barriers for patients by 92 
providing smear microscopy, Xpert/MTBRIF and treatment free of charge. A similar 93 
approach is necessary if CXRs become part of the diagnostic algorithms. 94 
 95 
 96 
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Box 1: Main topics covered by the survey questionnaire 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Question Domain 
Where can patients get a CXR, e.g. public hospital, private 
provider? 
Coverage and access of 
CXR 
Is CXR free in the public service? 
 
Access and cost CXR 
If CXR is not provided free of charge, how much does it 
cost? 
 
Cost of CXR 
Are there certain circumstances when CXR is provided free 
of charge, e.g. for children? 
 
Cost of CXR 
Is CXR part of the diagnostic algorithm in your country? 
 
Role of CXR in diagnostic 
algorithm 
Is smear microscopy provided free of charge in the public 
service in your country? 
 
Cost of diagnosis by smear 
microscopy  
Are TB patients in your country covered by a national health 
insurance scheme or other forms of social protection (e.g. 
cash transfer to cover the cost of TB diagnosis and 
treatment)? 
Availability of social 
protection/health 
insurance in the country 
If so, does the national health insurance cover the cost of 
CXR for TB patients? 
Coverage of TB patients by 
health insurance 
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Figure 1: Levels of costs reported by country experts 
 
 
 
World Bank income 
classification1 
Country included in the survey TB HBC List2 MDR-TB HBC List2 
Low-income economies 
Burkina Faso   
Chad   
Congo, Dem. Rep.   
Ethiopia   
Malawi   
Mozambique   
Senegal   
Zimbabwe   
Lower-middle-income 
economies 
Armenia   
Bolivia   
Ghana   
Indonesia   
Kyrgyzstan   
Mongolia   
Myanmar   
Nigeria   
Pakistan   
Sudan   
Vietnam   
Zambia   
Upper-middle-income 
Azerbaijan   
Botswana   
Brazil   
Dominican Republic   
 8 
Namibia   
Peru   
Venezuela   
 
 
1 World Bank country classification by income: low-income economies are defined as those 
with a gross national income (GNI) per capita, calculated using the World Bank 
Atlas method, of $1,025 or less in 2015; lower middle-income economies are those with a 
GNI per capita between $1,026 and $4,035; upper middle-income economies are those with 
a GNI per capita between $4,036 and $12,475. 
 
2 HBC countries list for TB and MDR-TB used by WHO for the period 2016-2020(11) 
 
 
